Japan Considers Suspending Mitsubishi Tanabe Pharma Operations
This article was originally published in PharmAsia News
Executive Summary
Japan's health authorities are considering suspension of Mitsubishi Tanabe Pharma operations for alleged falsified blood-product data by one of its units